Skip to main content
Clinical Trials/NCT05089760
NCT05089760
Not yet recruiting
Not Applicable

Microbiology, Antimicrobial Resistance and Outcomes of Neonatal Sepsis in Chinese Neonatal Intensive Care Units

Children's Hospital of Fudan University0 sites1,200 target enrollmentJanuary 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Antimicrobial Resistance
Sponsor
Children's Hospital of Fudan University
Enrollment
1200
Primary Endpoint
Overall mortality
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

Neonatal sepsis remains one of the most important cause of mortality and morbidities in China. This study will establish a prospective registral cohort of all infants with culture-proven neonatal sepsis in Chinese NICUs participating in the Chinese Neonatal Network (CHNN). The microbiology, antimicrobial resistance patterns and neonatal outcomes will be described in detail for this cohort.

Detailed Description

All infants with culture-proven sepsis in NICUs of CHNN will be enrolled in the study. Detailed data on microbiology, resistance pattern, neonatal mortality and morbidities will be collected and described. Risk factors for multi-resistant bacteria infections and for sepsis-related mortality will be identified.

Registry
clinicaltrials.gov
Start Date
January 1, 2024
End Date
December 31, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Admitted to CHNN NICUs from 2022.1.1 to 2023.12.31
  • Diagnosed with culture-proven sepsis

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Overall mortality

Time Frame: About 3 months from admission to discharge or death

Incidence of death during the study period

Secondary Outcomes

  • Incidence of septic shock(About 3 months from admission to discharge or death)
  • Incidence of multiorgan dysfunction(About 3 months from admission to discharge or death)
  • Sepsis-related mortality (within 7 days of sepsis)(About 3 months from admission to discharge or death)
  • Incidence of respiratory failure(About 3 months from admission to discharge or death)
  • Incidence of disseminated intravascular coagulation (DIC)(About 3 months from admission to discharge or death)
  • Incidence of necrotizing enterocolitis(About 3 months from admission to discharge or death)
  • Incidence of meningitis(About 3 months from admission to discharge or death)
  • Length of antibiotic treatment(About 3 months from admission to discharge or death)
  • Type and quantity of transfusion(About 3 months from admission to discharge or death)
  • Incidence of renal failure(About 3 months from admission to discharge or death)
  • Incidence of brain injury(About 3 months from admission to discharge or death)
  • Length of hospital stay(About 3 months from admission to discharge or death)

Similar Trials